VPTDF (VentriPoint Diagnostics) 3-Year Dividend Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is VentriPoint Diagnostics 3-Year Dividend Growth Rate?

VentriPoint Diagnostics VPTDF +0.29% 3-Year Dividend Growth Rate is 0.00% as of Jun. 2026. The stock has 5 warning signs investors should review. Among 223 Medical Devices & Instruments companies, VentriPoint Diagnostics ranks worse than 448430.04% on this metric.

VentriPoint Diagnostics's Dividends per Share for the three months ended in Jun. 2026 was $0.00.

The historical rank and industry rank for VentriPoint Diagnostics's 3-Year Dividend Growth Rate or its related term are showing as below:

VPTDF's 3-Year Dividend Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 5.6
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

VentriPoint Diagnostics's Dividend Payout Ratio for the three months ended in Jun. 2026 was 0.00. As of today, VentriPoint Diagnostics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


VentriPoint Diagnostics  (OTCPK:VPTDF) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

VentriPoint Diagnostics's Dividend Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Jun. 2026 )/ EPS without NRI (Q: Jun. 2026 )
=0/ 0
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VentriPoint Diagnostics 3-Year Dividend Growth Rate Related Terms>


VPTDF vs ABT, SYK, MDT: 3-Year Dividend Growth Rate Comparison

For the Medical Devices subindustry, VentriPoint Diagnostics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VentriPoint Diagnostics 3-Year Dividend Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where VentriPoint Diagnostics's 3-Year Dividend Growth Rate falls into.



VentriPoint Diagnostics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Dividend Growth Rate of 0.00% mean?
VentriPoint Diagnostics (VPTDF) has a 3-Year Dividend Growth Rate of 0.00% as of Jun. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on VentriPoint Diagnostics and its competitors. According to the industry distribution chart, VentriPoint Diagnostics ranks #999999 out of 223 companies in the Medical Devices & Instruments industry.
Is VentriPoint Diagnostics' 3-Year Dividend Growth Rate too high?
VentriPoint Diagnostics' current 3-Year Dividend Growth Rate is 0.00%. Based on the distribution chart, VentriPoint Diagnostics ranks #999999 out of 223 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does VentriPoint Diagnostics' 3-Year Dividend Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VentriPoint Diagnostics ranks #999999 out of 223 companies for 3-Year Dividend Growth Rate. This places VentriPoint Diagnostics in the lower half of its industry. The industry median 3-Year Dividend Growth Rate is 5.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Dividend Growth Rate among Medical Devices & Instruments companies is 5.60, based on 223 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on VentriPoint Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Dividend Growth Rate is 5.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VentriPoint Diagnostics's current 3-Year Dividend Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current 3-Year Dividend Growth Rate of 0.00%. The current 3-Year Dividend Growth Rate is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current 3-Year Dividend Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VentriPoint Diagnostics Business Description

Other Exchanges VPT:Canada
Address 18 Hook Avenue, Unit 101, Toronto, ON, CAN, M6P 1T4
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.